The Annual Crab Trap Competition, held during the BioHealth Capital Region Forum at US Pharmacopeia, showcased some of the most innovative start-ups from across the region and around the world. This year, Perfusion Medical of Reston, VA, was named the winner of the competition, taking home the $10,000 cash prize from BHI along with $25,000 in IT and cybersecurity services provided by InfoPathways.

Perfusion Medical’s CEO, Gerard Eldering, delivered the winning pitch, highlighting the company’s therapy PM-208, which is designed to restore capillary blood flow and oxygen delivery following trauma or ischemic injury.

In addition, Chariot Biosciences, based in Baltimore, MD, was selected to receive $10,000 in CRO services sponsored by Accelevir Diagnostics and Noble Life Sciences. 

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), today announced a new funding opportunity through its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. With cutting-edge production technologies, the program seeks to establish the U.S. as a frontrunner in advanced manufacturing methods for high-quality genetic medicines. 

Genetic medicines have an unrivaled potential to treat the root causes of rare genetic conditions, cancer, chronic diseases like cystic fibrosis and liver or cardiovascular disorders, autoimmune diseases, and infectious diseases. The promise of genetic medicines lies in the ability to make treatments in different formats. Their development is often hindered by the high cost and complexity of manufacturing and quality testing, centralized facilities with specialized equipment needs, and ultracold shipping requirements.  

By Sara Gilgore – Staff Reporter, Washington Business Journal British pharmaceutical giant GSK PLC is making a significant investment in its commercial manufacturing complex in Rockville, even as it prepares to move its nearby vaccines research and development campus out of the region.

GSK said it intends to pour part of a $30 billion investment in its U.S. supply chain infrastructure and R&D over five years into its suburban Maryland hub and a handful of other manufacturing facilities across the country.

The company (NYSE: GSK) is still finalizing “specific details around individual facility investments,” a GSK spokesperson told me over email, declining to share more at this point.

Date: 10/3/2025

Time: 10:00 AM - 11:15 AM (EDT)

Registration Deadline: 10/2/2025 4:00 PM (EDT)

This comprehensive training program is designed to equip aspiring entrepreneurs and small business owners with the essential tools and knowledge to navigate the complexities of business ownership. Starting with foundational concepts, participants will learn how to plan their business ownership journey and develop a robust business plan. The program covers critical financial management topics, including accounting, finance, and taxes, while also delving into effective market research and the art of crafting a winning marketing plan. Attendees will gain practical insights into

In September 2025, the U.S. government announced a series of new and modified contracts to strengthen biodefense preparedness through procurements from Emergent BioSolutions, a Maryland-based company specializing in medical countermeasures (MCMs). The awards, made through the Biomedical Advanced...

The skyline above the Fontaine Research Park temporarily includes two cranes as construction continues on projects such as the Paul and Diane Manning Institute of Biotechnology. 

Last spring, the institute’s first director was hired after a career in the pharmaceutical industry that he now hopes will have a new chapter in Virginia. 

“When I joined on May 1, I was walking the site...

ROCKVILLE, Md., Sept. 23, 2025 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, today announced it will be initiating clinical evaluation of R-2487 in SjD.

The new SJD study will be funded by the National Institute of Dental and Craniofacial Research (NIDCR) and builds on emerging clinical and biomarker data from Rise's ongoing clinical trial of R-2487 in RA.

R-2487 is a first-in-class targeted immune...

ROCKVILLE, Md.--(BUSINESS WIRE)--PQE Group is proud to announce it has been honored with the Stellar Business “Best Life Sciences Company in Maryland” Award. Stellar Business Awards is a premier recognition platform celebrating outstanding businesses, entrepreneurs, and industry leaders across multiple sectors. Its mission is to honor innovation, leadership, and success, giving businesses the visibility and credibility they deserve. It honors outstanding businesses, entrepreneurs, and industry leaders who are making a significant impact in their fields.

Selected as this year’s award recipient, PQE US was recognized by the Stellar Business Award Committee based on...